Sanofi stock holds steady as analysts see upside from asthma pipeline
Published on 08/25/2026 at 07:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Sanofi (FR0000127771) stock is trading in the high 70-euro range in late August 2026, with recent analyst commentary pointing to upside potential from a developing asthma antibody and continued growth from key drug Dupixent as of August 24, 2026.
Analysts highlight valuation and asthma pipeline
According to a recent assessment of Sanofi shares, the stock was quoted at 78.28 EUR with a small daily decline of 0.06 percent on August 24, 2026. In the same discussion, the valuation implied an upside potential of roughly one third from that price to a target area around 105 EUR, suggesting that the shares trade at a discount to the analyst view of fair value. The commentary also emphasized that Sanofi stock is historically inexpensive based on this target-to-price gap and current earnings expectations.
The same coverage underlined that Sanofi is advancing a new antibody candidate aimed at asthma, which could add another pillar to its respiratory and immunology portfolio if clinical data continue to support efficacy and safety. The potential for this candidate is important because the current blockbuster asthma and atopic dermatitis treatment Dupixent faces patent expiry risk from 2032, which could pressure long-term revenue growth if replacement products are not ready. For investors, the combination of a discounted share price and a developing asthma pipeline is central to the medium-term equity story.
Recent earnings growth driven by Dupixent
Recent reporting on Sanofi's second-quarter 2026 performance highlighted that Dupixent remained the main growth driver. In that quarter, sales of Dupixent increased by 37.6 percent compared with the same period a year earlier, underscoring the drug's continued expansion across indications and geographies. This high growth rate helped management raise the companywide targets for 2026.
Following this strong quarter, Sanofi now aims for revenue growth of 10 percent at constant exchange rates for 2026, compared with prior guidance that implied a lower growth band. The decision to lift the full-year outlook reflects confidence that Dupixent and other key therapies can offset headwinds from pipeline adjustments and cost pressures. When a single product contributes such a large share of incremental revenue, however, the concentration risk naturally increases over time.
The same sources noted that earlier in the summer of 2026 Sanofi decided to halt development of the immune therapy amlitelimab in atopic dermatitis, after data did not support global regulatory filings in that indication. While this move removes one potential near-term launch, it also frees research and development resources for other late-stage assets, including the asthma antibody and vaccines. Management has framed these changes as part of a shift toward more disciplined capital allocation in research projects.
Regulatory news and vaccine progress
Beyond Dupixent and the asthma pipeline, Sanofi has reported progress in vaccines. In a recent clinical study of an H5N8 influenza vaccine candidate, results as of August 19, 2026 indicated that the program could support a long-term position in pandemic preparedness. Such a positioning is strategically important, because pandemic and seasonal flu products can provide relatively steady revenue streams that complement more volatile specialty-drug businesses.
The company also obtained European Union approval for the meningococcal vaccine MenQuadfi for use in infants from six weeks of age, a decision reported a little more than three weeks before August 24, 2026. This label extension broadens the drug's addressable population and could support incremental vaccine revenue in coming years. Vaccines are a core segment for Sanofi, and early-life immunization approvals tend to have long product lifecycles because they become embedded in national vaccination schedules.
On the regulatory risk side, recent reporting has pointed to concerns from the European Medicines Agency related to a specific indication of Dupixent, which led Sanofi to withdraw that particular use from the approval dossier. In addition, an antitrust investigation in the European Union is examining allegations that Sanofi made misleading claims about influenza vaccines. These developments illustrate the complex regulatory environment in which large pharmaceutical companies operate and underscore that product approvals and label expansions can be accompanied by legal and compliance risk.
Mixed signals from the pipeline and research strategy
Sanofi's pipeline has delivered both setbacks and advances in recent months. Alongside the discontinuation of amlitelimab in atopic dermatitis, the company has also reassessed a successor candidate to Dupixent and decided to stop development after reviewing data that did not meet internal thresholds. Decisions like these reduce short-term expectations for follow-on products but can be viewed as part of a more selective research strategy that aims to allocate capital to the most promising assets.
At the same time, Sanofi has reported positive data from a study with the enzyme replacement therapy Nexviazyme, in which the trial met all key endpoints. The company also secured approval from the U.S. Food and Drug Administration for a wearable injector form of a blood cancer drug, which offers patients a more convenient administration option and may improve adherence. These incremental pipeline and lifecycle-management wins help diversify the growth profile beyond Dupixent and support the case that Sanofi is not solely dependent on one blockbuster product.
However, external observers have also reported that management itself has acknowledged weaknesses in past decision-making processes that may have slowed or complicated pipeline progress. In response, Sanofi has promised to apply more disciplined research and development governance, including clearer go or no-go criteria and stricter portfolio reviews. For equity holders, the key question is whether this cultural and procedural shift will translate into a steadier stream of high-quality late-stage assets over the rest of the decade.
Analyst opinions and target prices
Analyst coverage of Sanofi remains mixed but leans positive. One detailed analysis from August 24, 2026 reiterated a 'Buy' view on the shares and set a target of 105 EUR. With the stock currently trading close to 78.5 EUR, that target implies upside of more than 30 percent from recent levels. The same report mentioned that the share price was slightly positive at 78.42 EUR in trade at 8:44 a.m. Central European Time on August 24, 2026, up 0.11 percent on the day.
Another recent article noted that the shares were changing hands at 78.50 EUR on the same date, down 0.6 percent, and that the stock had declined 5.3 percent since the start of 2026. Despite this year-to-date drop, the price still stood 1.6 percent above its 200-day moving average, an indicator often used to gauge medium-term trend direction. The combination of a slightly negative year-to-date performance and a price modestly above the long-term trend line indicates a stock that has retraced some gains but remains on a gradual upward path.
Other analyst houses have taken more cautious positions. One firm initiated coverage with a neutral rating and a holding stance on August 11, 2026, while another reduced its fair value estimate from 86 EUR to 82 EUR on August 10, 2026. These differences reflect uncertainties around future pipeline execution, regulatory outcomes, and the eventual erosion of Dupixent's exclusivity. Nevertheless, the existence of both bullish and neutral views can provide additional liquidity and trading opportunities for investors who have a differentiated perspective on Sanofi's long-term prospects.
Operational challenges and regulatory scrutiny
Sanofi has also faced operational and regulatory challenges. A recent report described a warning letter from the U.S. Food and Drug Administration related to a manufacturing site in Waterford, which underscores the importance of maintaining high quality standards in biologics and vaccine production. Such letters typically require corrective actions and may temporarily constrain output or increase costs, although they do not automatically halt production if the issues are remediable.
Even as it works through these issues, Sanofi's research organization continues to report successes, such as the positive H5N8 influenza vaccine data and the Nexviazyme study. Management has also indicated that acquisitions could play a role in strengthening the development pipeline, especially in the context of the expected expiration of Dupixent patents in 2032. Any such deals would likely be targeted at assets that fit Sanofi's core strengths in immunology, oncology, and vaccines.
From a risk perspective, investors must weigh the potential for further regulatory investigations, including the European antitrust probe into flu vaccine marketing, against the revenues generated by the existing portfolio. Regulatory settlements, if any, could affect operating margins in specific years, but diversified product portfolios and cost-savings programs often mitigate the long-term impact on earnings.
Representative product: Dupixent
Dupixent is a monoclonal antibody that targets interleukin-4 and interleukin-13 pathways and is used to treat conditions such as moderate-to-severe atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. The therapy is co-developed with an international partner and has become one of Sanofi's largest revenue contributors. In the second quarter of 2026, Dupixent revenue increased by 37.6 percent year over year, reflecting both new patient starts and geographic expansion.
Because Dupixent is already approved across multiple indications and continues to generate double-digit growth, it forms the backbone of Sanofi's immunology franchise. However, the expected expiration of key patents in 2032 means that biosimilar competition could emerge in the following years, which is why Sanofi is investing in next-generation antibodies and combination therapies in adjacent indications. For patients, the drug's success has expanded treatment options for serious chronic inflammatory diseases that previously had limited therapies.
Sanofi stock and recent trading levels
Sanofi shares trade primarily on Euronext Paris under the company's home listing, with the stock quoted at 78.50 EUR in one report on August 24, 2026 and at 78.42 EUR in another around the same date. These levels place the price slightly above the 200-day moving average, with the stock's year-to-date performance showing a decline of 5.3 percent compared with the start of 2026. The valuation gap between current prices in the high 70s and analyst targets in the low hundreds forms a central part of the investment debate.
For investors, the key numerical signals are the combination of a 37.6 percent year-on-year increase in Dupixent sales in the second quarter of 2026, a raised companywide revenue growth target of 10 percent at constant currencies for 2026, and a share price in the high 70-euro range that some analysts believe leaves more than 30 percent upside to their fair-value estimates. How that gap closes will depend on execution in the pipeline, management's ability to handle regulatory scrutiny, and broader market conditions for large-cap pharmaceutical stocks.
Read more
More on Sanofi stock and its recent performance can be found in specialized financial and market commentary that tracks the company's earnings, pipeline news, and analyst updates in detail.
Sanofi vaccines and pandemic preparedness
Within Sanofi's broader portfolio, vaccines play a crucial role in balancing cyclical and structural revenue drivers. The H5N8 influenza vaccine candidate that recently generated positive data is part of a strategy to remain a key partner for governments and international organizations in both seasonal and pandemic flu preparedness. If successfully developed and approved, such vaccines can support volumes over many years, due to ongoing immunization needs and periodic booster campaigns.
MenQuadfi, another major vaccine, recently received European approval for use in infants from six weeks of age, which broadens its market potential. Early-life indications often lead to stable demand because they become embedded in standard vaccine schedules. For Sanofi, incremental approvals like this can support modest but durable growth that complements larger swings from blockbuster specialty drugs. The combination of innovation in vaccines and in specialty medicines is central to the company's growth strategy.
Corporate strategy and capital allocation
Sanofi's decision to halt amlitelimab in atopic dermatitis and to drop a successor candidate to Dupixent reflects a shift toward more selective capital allocation in research and development. By tightening criteria for late-stage programs and emphasizing projects with clearer paths to regulatory approval and commercial success, management aims to improve the return on R&D spending. This is particularly important in an environment where large pharmaceutical companies face both rising development costs and greater scrutiny from payers.
At the same time, Sanofi has signaled that targeted acquisitions could supplement internal research efforts. These deals would likely focus on assets that strengthen existing franchises, such as immunology or rare diseases, rather than large-scale diversification into unfamiliar therapeutic areas. The balance between internal development and external licensing or acquisitions will shape Sanofi's growth profile into the 2030s, especially as key products such as Dupixent approach the end of their exclusivity periods.
Balance of risks and opportunities
Overall, Sanofi's current situation combines solid earnings momentum from Dupixent and other key drugs, a growing vaccines franchise, and a pipeline that shows both promise and vulnerability. On the opportunity side, the 37.6 percent growth in Dupixent revenue in the second quarter of 2026 and the raised 10 percent revenue growth target for 2026 signal that the core business is performing strongly. On the risk side, pipeline discontinuations, regulatory investigations, and the eventual loss of exclusivity on major products create uncertainty that investors must price into the shares.
For investors evaluating Sanofi stock as of late August 2026, the central questions revolve around whether management can successfully convert its current suite of clinical programs, including the new asthma antibody and H5N8 vaccine, into sustainable revenue streams before major patent cliffs arrive, and whether cost discipline and portfolio optimization can protect margins even in the face of regulatory and competitive pressures. The current share price, which remains below some analyst targets despite solid operating metrics, suggests that the market is cautiously optimistic but still demands proof of execution.
Fact box
Company: Sanofi S.A.
ISIN: FR0000127771
Ticker: SAN
Exchange: Euronext Paris
